- Japan
- /
- Life Sciences
- /
- TSE:7079
WDB coco First Quarter 2025 Earnings: EPS: JP¥99.80 (vs JP¥67.03 in 1Q 2024)
WDB coco (TSE:7079) First Quarter 2025 Results
Key Financial Results
- Revenue: JP¥1.28b (up 23% from 1Q 2024).
- Net income: JP¥240.0m (up 49% from 1Q 2024).
- Profit margin: 19% (up from 15% in 1Q 2024). The increase in margin was driven by higher revenue.
- EPS: JP¥99.80 (up from JP¥67.03 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
WDB coco Earnings Insights
Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in Asia.
Performance of the market in Japan.
The company's shares are up 25% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with WDB coco, and understanding them should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if WDB coco might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7079
WDB coco
Provides contract services to pharmaceutical companies in Japan.
Flawless balance sheet and undervalued.